Abstract: A 1,3-dioxane derivative and a liquid crystal composition containing it as expressed by the general formula ##STR1## (where R is a straight chain alkyl group of carbon number 1 to 10, A is a single bond or --CH.sub.2 CH.sub.2 -- group, n is 0 or 1, and the cyclohexane ring and 1,3-dioxane ring are respectively in trans form is disclosed.) The 1,3-dioxane derivative represented by general formula (I) has a very large dielectric anisotropy and a small birefringence. Liquid crystal compositions containing (I) can be driven at low voltage and will provide a liquid crystal display apparatus with a wide visual angle.

Abstract: Compounds of the formula ##STR1## and liquid crystalline mixtures containing same.

Abstract: Compounds of the formula ##STR1## wherein A.sup.1 denotes a single covalent bond and A.sup.2 denotes 1,4-phenylene or trans-1,4-cyclohexylene or A.sup.1 denotes trans-1,4-cyclohexylene and A.sup.2 denotes a single covalent bond; X.sup.1 signifies fluorine or chlorine; X.sup.2 represents fluorine or, when X.sup.1 signifies chlorine, also hydrogen or chlorine; and R.sup.1 signifies 1E-alkenyl with 2 to 12 carbon atoms,their manufacture, liquid crystalline mixtures which contain such compounds and their use for electro-optical purposes.

Abstract: A composition for removing or inactivating harmful components including virus from blood or other extracellular liquids comprises a crownether compound substituted on a polysaccharide, preferably dextrane. The composition may be soluble in water, preferably for intraveneous application, or insoluble for extracorporeal application.

Abstract: Compounds of the formula ##STR1## wherein X.sup.1 denotes fluorine or chlorine and X.sup.2 denotes hydrogen, fluorine or chlorine; R.sup.1 is 3E-alkenyl, 4-alkenyl, 2E-alkenyloxy or 3-alkenyloxy; n stands for the number 0 or 1; one of the groups Y.sup.1 and Y.sup.2 is a single covalent bond, --COO--, --OOC--, --CH.sub.2 CH.sub.2 --, --CH.sub.2 O-- or --OCH.sub.2 -- and the other of the groups Y.sup.1 and Y.sup.2 is a single covalent bond; and rings A.sup.1 and A.sup.2 each individually are substituted or unsubstituted trans-1,4-cyclohexylene, in which optionally 2 non-adjacent CH.sub.2 groups are replaced by oxygen, or substituted or unsubstituted 1,4-phenylene, in which optionally 1 CH group or 2 CH groups is/are replaced by nitrogen; with the proviso that X.sup.2 denotes fluorine or chlorine and/or Y.sup.1 or Y.sup.2 denotes --CH.sub.2 O-- or --OCH.sub.2 -- when simultaneously X.sup.1 is fluorine and R.sup.1 is 3E-alkenyl,and their use for liquid crystalline mixtures and electro-optical purposes.

Abstract: New intermediates and processes for the preparation of vitamins A and E, which are the acetals of 5,6-dihalo-3-methyl-3-hydroxyhexanal or of 6-halo-3-hydroxy-3-methyl-5-hexenal or 3-methyl-3-hydroxy-5-hexenal, as well as processes for making the intermediates. After dehydrohalogenation and dehydration these intermediates are condensed directly with .beta.-ionone or with 2-methyl-2-heptene-6-one to synthesize vitamins A and E respectively.

Abstract: Compounds of the formula ##STR1## wherein n stands for the number 0 or 1; rings A, B and C each independently represent trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl or unsubstituted or fluoro-substituted 1,4-phenylene; R.sup.1 denotes 3E-alkenyl with 4 to 12 carbon atoms, 4-alkenyl with 5 to 12 carbon atoms or, when ring A represents trans-1,4-cyclohexylene or trans-1,3-dioxane-2,5-diyl, also 1E-alkenyl with 2 to 12 carbon atoms; and R.sup.2 is hydrogen or C.sub.1 -C.sub.10 -alkyl, their manufacture as well as liquid crystalline mixtures which contain such compounds and their use for electro-optical purposes.

Abstract: Fluorine-containing liquid crystal compounds are provided. The compounds comprise a fluorocarbon terminal portion having at least one catenary ether oxygen and a hydrocarbon terminal portion, the terminal portion being connected by a central core, the compounds having smectic mesophases or having latent smectic mesophases.

Abstract: This invention provides certain sulfonimidamide compounds, formulations and method of use of these compounds in treating susceptible neoplasms.

Abstract: Phenyldioxanes of the formula I ##STR1## wherein R.sup.1 is an alkyl or alkenyl residue each with up to 16 C atoms, wherein one or two non-adjacent CH.sub.2 groups of these residues may be replaced by --CO--O-- or --O--CO--,Q.sup.1 and Q.sup.2 are each independently ##STR2## L.sup.1 and L.sup.2 are each independently F or H, and Y is Cl, F, CN, CF.sub.3, OCF.sub.3 or OCF.sub.2 H,m and n is 0 or 1,are suitable as components of liquid crystal media.

Abstract: Novel 2,5-disubstituted heterocyclic compounds of the formula I ##STR1## in which n is 1 to 10,Het is ##STR2## Ring A is trans-1,4-cyclohexylene or, in the case where Het= ##STR3## X=--OCF.sub.3 or --OCHF.sub.2 and/or Y=Z=F, is alternatively 1,4-phenylene,X is CN, F, Cl, --CF.sub.3, --OCF.sub.3 or --OCHF.sub.2, andY and Z are each, independently of one another, H or F, can be used as components of liquid-crystalline media.

Abstract: Trans-2-phenyl-5-trans-4'-alkylcyclohexyl-1,3-dioxane derivatives represented by the general formula: ##STR1## wherein R is a linear alkyl group of 1 to 10 carbon atoms, A is a single covalent bond or a --CH.sub.2 CH.sub.2 -- group, X is F or CN, Y is F if X is CN or Y is H or F if X is F, and the cyclohexane ring and the 1,3-dioxane ring are trans isomers. The 1,3-dioxane derivatives have large positive dielectric constant anisotropy (.DELTA..epsilon.), small birefringence (.DELTA.n) and have good compatibility with other liquid crystal compounds. The dioxane derivatives may be included in liquid crystal compositions for improved display devices having a low threshold voltage, a low driving voltage and a wide visual angle.

Abstract: The present invention relates to propanamines of general formula (I) ##STR1## in which: R1 is a phenyl radical optionally mono-, di- or trisubstituted in an identical or different manner with halogen atoms, or lower alkyl, lower haloalkyl or lower alkoxy radicals;R2 is a lower alkyl radical,R3 and R4 are a hydrogen atom or a lower alkyl, lower alkenyl or lower cycloalkyalkyl radical,R5 is a 5-to 7-membered cycloalkyl radical or a phenyl radical, andW represents a heterocycle .dbd.C[Q--(CH.sub.2).sub.n --Q] in which Q is an oxygen or sulfur atom and n is 2 or 3,and their acid addition salts with pharmaceutically acceptable acids. The invention also relates to antidiarrheal pharmaceutical compositions comprising the claimed propanamines.

Abstract: Compounds of the formula ##STR1## wherein X.sup.1 denotes fluorine or chlorine and X.sup.2 denotes hydrogen, fluorine or chlorine; R.sup.1 is 3E-alkenyl, 4-alkenyl, 2E-alkenyloxy or 3-alkenyloxy; n stands for the number 0 or 1; one of the groups Y.sup.1 and Y.sup.2 is a single covalent bond, --COO--, --OOC--, --CH.sub.2 CH.sub.2 --, --CH.sub.2 O-- or --OCH.sub.2 -- and the other of the groups Y.sup.1 and Y.sup.2 is a single covalent bond; and rings A.sup.1 and A.sup.2 each individually are substituted or unsubstituted trans-1,4-cyclohexylene, in which optionally 2 non-adjacent CH.sub.2 groups are replaced by oxygen, or substituted or unsubstituted 1,4-phenylene, in which optionally 1 CH group or 2 CH groups is/are replaced by nitrogen; with the proviso that X.sup.2 denotes fluorine or chlorine and/or Y.sup.1 or Y.sup.2 denotes --CH.sub.2 O-- or --OCH.sub.2 -- when simultaneously X.sup.1 is fluorine and R.sup.1 is 3E-alkenyl,and their use for liquid crystalline mixtures and electro-optical purposes.

Abstract: Disclosed are trifluoromethylcyclohexane derivatives of the formula I ##STR1## whereinR is an alkyl or alkenyl radical having up to 18 C atoms which is unsubstituted or substituted by CN or by at least one halogen, and in which one or more non-adjacent CH.sub.2 groups may be replaced by a radical selected from the group comprising --O--, --S--, --CO--, --O--CO--, --CO--O-- and --C.tbd.C--,A.sup.1 and A.sup.2 are each, independently of one another,a) a 1,4-phenylene radical, in which one or two CH groups may be replaced by N,b) a 1,4-cyclohexylene radical, in which one or two non-adjacent CH.sub.2 groups may be replaced by --O-- or --S--,c) a 1,4-cyclohexenylene, piperidine-1,4-diyl, 1,4-bicyclo[2,2,2]-octylene or naphthalene-2,6-diyl radical,it being possible for the radicals a) and b) to be monosubstituted or polysubstituted by halogen atoms or cyano and/or methyl groups, ##STR2## Z.sup.1 and Z.sup.2 are each, independently of one another, --CO--O--, --O--CH--, --CH.sub.2 CH.sub.2 --, --CH(CN)--CH.sub.

Abstract: Compounds of the formula ##STR1## wherein n stands for the number 0 or 1; R.sup.1 denotes a group R.sup.3 or R.sup.3 --A.sup.3 --Z.sup.2 -- and R.sup.2 denotes a group R.sup.4 or R.sup.4 --A.sup.4 --Z.sup.3 --; ring A.sup.1 signifies unsubstituted or halogen-, cyano- and/or methyl-substituted 1,4-phenylene in which optionally 1 CH group or 2 CH groups is/are replaced by nitrogen; A.sup.3, A.sup.4 and ring A.sup.2 each independently represent unsubstituted or halogen-, cyano- and/or methyl-substituted 1,4-phenylene in which optionally 1 CH group or 2 CH groups is/are replaced by nitrogen or trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, 1-cyano-trans-1,4-cyclohexylene, bicyclo[2.2.2]octane-1,4-diyl, naphthalene-2,6-diyl, tetralin-2,6-diyl or trans-decalin-2,6-diyl; Z.sup.1, Z.sup.2 and Z.sup.3 each independently signify a single covalent bond, --COO--, --OOC--, --CH.sub.2 O--, --OCH.sub.2 --, --CH.tbd.C--, --(CH.sub.2).sub.3 O--, --O(CH.sub.2).sub.3 --, --(CH.sub.2).sub.4 -- or the trans form of --CH.

Abstract: Seco-mevinic acid derivatives are provided which have the structure ##STR1## including all stereoisomers thereof, wherein Z is ##STR2## R is H, alkali metal or lower alkyl, R.sup.1 is H, lower alkyl, aryl, lower alkoxy, cycloalkyl, heteroaryl, aralkyl, heteroaralkyl or heterocyclic; R.sup.2 is lower alkyl, cycloalkyl or aralkyl, and X is O or NR.sup.5 wherein R.sup.5 is H or lower alkyl, and are HMG CoA reductase inhibitors and thus are useful as antihypercholesterolemic agents and in treating atherosclerosis.New intermediates for preparing the above seco-mevinic acid derivatives are also provided.

Abstract: Novel perfumery chemicals having a cyclic acetal structure and providing a variety of perfume notes, especially amber, are described. They are prepared by reacting specified diols and aldehydes/ketones.

Abstract: Compounds of the formula ##STR1## wherein n stands for the number 0 or 1; rings A, B and C each independently represent trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl or unsubstituted or fluoro-substituted 1,4-phenylene; R.sup.1 denotes 3E-alkenyl with 4 to 12 carbon atoms, 4-alkenyl with 5 to 12 carbon atoms or, when ring A represents trans-1,4-cyclohexylene or trans-1,3-dioxane-2,5-diyl, also 1E-alkenyl with 2 to 12 carbon atoms; and R.sup.2 is hydrogen or C.sub.1 -C.sub.10 -alkyl,their manufacture as well as liquid crystalline mixtures which contain such compounds and their use for electro-optical purposes.

Abstract: An improved process for the purification of cyclic ketene acetals such as 2-methylene-1,3-dioxepane is provided. This process entails the purification of the cyclic ketene acetal by distillation in the presence of a solvent and an amine.

Abstract: The present invention relates to a process for preparing halo acetals of ethylenic aldehydes by reaction of a halogen cation with enamine followed by a hydrolysis and reaction with an alcohol, a glycol or an orthoformate. These halo acetals are used as intermediate for the synthesis of vitamins A and E.It also relates to a new compound of formula (IV), ##STR1## to a process for preparing it from halo acetals of ethylenic aldehydes by reaction with triethyl phosphate, and to its use for the preparation of retinal by reaction with .beta.-ionylideneacetaldehyde.

Abstract: New intermediates and processes for the preparation of vitamins A and E, which are the acetals of 5,6-dihalo-3-methyl-3-hydroxyhexanal or of 6-halo-3-hydroxy-3-methyl-5-hexenal or 3-methyl-3-hydroxy-5-hexenal, as well as processes for making the intermediates. After dehydrohalogenation and dehydration these intermediates are condensed directly with .beta.-ionone or with 2-methyl-2-heptene-6-one to synthesize vitamins A and E respectively.

Abstract: The silicon-containing phenoxy ethers are of the formula III: ##STR1## wherein R.sup.1 and R.sup.2 which may be the same or different are selected from H, --R.sup.3 --X, aliphatic hydrocarbyl having 1-6 carbon atoms or aryl, or substituted derivatives thereof, provided that not more than one of R.sup.1 and R.sup.2 is H;R.sup.3 is a divalent C.sub.1 -C.sub.30 aliphatic and/or aromatic hydrocarbyl group which may optionally be substituted, or interrupted, by a hetero atom;R.sup.4 and R.sup.5 which may be the same or different are H, ##STR2## or an ortho para directing activating group for aromatic electrophilic substitution, other than an amine;and X is a reactive functional group capable of undergoing an acid-catalyzed electrophilic aromatic substitution reaction with a phenol, for example an aldehyde group. They can be polymerized to produce silicone-modified polymers of the phenol-aldehyde type without the use of free aldehyde.

Abstract: A ferroelectric liquid crystalline mixture containing at least one optically active compound of the general formula ##STR1## wherein X.sup.1 denotes a single covalent bond, --COO--, --OOC--, --CH.sub.2 CH.sub.2 --, --OCH.sub.2 -- or --CH.sub.2 O--; one of rings A.sup.1, A.sup.2 and A.sup.3 represents trans-m-dioxan-2,5-diyl and the other two of rings A.sup.1, A.sup.2 and A.sup.3 each independently represent unsubstituted 1,4-phenylene or 1,4-phenylene substituted with cyano, halogen or lower alkyl; R.sup.1 and R.sup.2 each independently signify an optionally halogen-substituted alkyl group with up to 18 carbon atoms in which optionally 1 CH.sub.2 group or 2 non-adjacent CH.sub.2 groups is/are replaced by --O--, --CO--, --COO-- and/or --OOC--,as well as novel compounds falling under formula I and ferroelectric electrode-optical indicating devices including same.

Abstract: Novel odorants, namely acetals and ketals of alkyl-substituted oxo-tetralins and oxo-indanes, are described.

Abstract: Achiral fluorine-containing liquid crystal compounds are provided. The compounds comprise a fluorocarbon terminal portion and a hydrocarbon or another fluorocarbon terminal portion, the terminal portions being connected by a central core, the compounds having smectic mesophases or having latent smectic mesophases. The compounds are useful in liquid crystal display devices both along and in mixtures with other materials. Also provided is a process for preparing these compounds.

Abstract: Novel pyrazole amide and an insecticidal and miticidal composition containing the pyrazole amide as an active ingredient are described.The pyrazole amide according to the present invention shows excellent insecticidal and miticidal activities.

Abstract: 2-(3', 4'-difluorophenyl)-1,3-dioxane derivatives represented by the general formula: ##STR1## wherein R is a linear alkyl group having from 1 to 8 atoms, and having large positive dielectric constant anisotropy (.DELTA..epsilon.) and small refractive index anisotropy (.DELTA.n). The dioxane derivatives may be included in liquid crystal compositions for improved display devices having a low threshold voltage, a low driving voltage and a wide visual angle.

Abstract: A process is described for the improved synthesis of the optically pure C.sub.10 -C.sub.24 fragment of the macrolide structure of the immunosuppressant FK-506. This compound is also useful as an intermediate for preparing FK-506 derivatives.

Abstract: A process for the preparation of optically active 3-demethylmevalonic acid derivatives of the formula I ##STR1## (3,5-dihydroxy carboxylic acid derivatives) or of the formula II ##STR2## in which R, R.sup.1 and Y have the indicated meanings, is described. The invention furthermore relates to aldehydes of the formula XII ##STR3## in which M represents the indicated protective groups.

Abstract: The present application discloses novel potassium salts of particular tellurium and selenium compounds which are useful for the stimulation of the production of cytokines.

Abstract: A novel complex of a class of tellurium and selenium compounds is disclosed, which is based on a complexing agent and the particular compound to be complexed.

Abstract: The invention concerns novel therapeutic agents containing a (Z)-(2-alkoxyalkyl- or 2-aryloxyalkyl-4-phenyl-1,3-dioxan-5-yl)alkenoic acid, or a related tetrazole derivative, which antagonizes one or more of the actions of thromboxane A.sub.2, together with a compound which inhibits the synthesis of thromboxane A.sub.2. The compositions are useful as medicines in treating a variety of diseases or medical conditions in which thromboxane A.sub.2 and/or other prostanoid contractile substances are involved.

Abstract: The invention concerns novel pharmaceutical compositions containing a 4(Z)-6-(2,4-diphenyl-1,3-dioxan-5-yl)-alkenoic acid which antagonizes one or more of the actions of thromboxane A.sub.2, together with a compound which inhibits the synthesis of thromboxane A.sub.2. The compositios are useful as medicines in treating a variety of diseases or medical conditions in which thromboxane A.sub.2 and/or other prostanoid contractile substances are involved.

Abstract: Disclosed is a process for the production of acids of the formula ##STR1## wherein R is 2-fluoro-4-(1,1'-biphenyl), 4-(2-methylpropyl)phenyl, 6-methoxy-2-napthyl, 3-benzophenyl, 4-(2-thienylcarbonyl)-phenyl or 7-chlorocarbazole-3-yl which comprises contacting an organometallic compound of the formula R--M--R.sub.

Abstract: A process for producing carotenoids and carotenoid intermediates via reduction of sulfonyl polyenes with a dithionite in the presence of ammonia or an aliphatic amine, including novel intermediates in this process, which carotenoids are known coloring agents for foodstuffs, animal feeds, pharmaceuticals, etc.

Abstract: Novel unnatural ceramide related compounds, for instance, (2S, 3S)-2-tetracosanamido-octadecane-1,3-diol are herein provided, which are useful as intermediates in preparing ceramide moieties employed in the preparation of glycolipids and gangliosides known as tumor markers or molecular markers and which are prepared by, for instance, subjecting a chiral compound represented by the following formula: ##STR1## to deacetal treatment.

Abstract: 1,3,5-Nonatriene derivatives of formula: ##STR1## in which R.sub.1 and R.sub.2, together with the carbon atom to which they are linked, form a carbonyl group, or each of R.sub.1 and R.sub.2 denotes alkoxy or R.sub.1 and R.sub.2 together form an alkylenedioxy radical, which may be made by reaction of a butadiene derivative of formula: ##STR2## in which R is alkyl or phenyl, with a butanal ketoacetal of 10 formula: ##STR3## followed by reaction of the product with a halomethyltriphenylphosphonium halide, are useful intermediates e.g. for the production of phytol.

Abstract: The invention relates to the use of trifluorotoluene derivatives of the formula I ##STR1## in which R.sup.1 is alkyl having 1 to 12 carbon atoms in which, in addition, one or more non-neighboring CH.sub.2 groups may be replaced by --O--, --CO--, --O--CO--, --CO--O--, --O--CO--O--, --CH-halogen, --CH--CN-and/or --CH=CH--,A.sup.1 and A.sup.2, in each case independently of one another, are 1,4-phenylene in which, in addition, one or more CH groups may be replaced by N, trans-1,4-cyclohexylene in which, in addition, one or two non-neighboring CH.sub.2 groups may be replaced by --O--and/or --S--, or 1,4-bicyclo(2,2,2)octylene, each of which is unsubstituted or monosubstituted or poly-substituted by halogen, nitrile and/or CH.sub.3,Z.sup.1 and Z.sup.2, in each case independently of one another, are --CO--O--, --O--CO--, --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 CH.sub.2 -- or a single bond, andn is 0 or 1,as components of chiral tilted smectic phases.

Abstract: The invention relates to a process for preparing the ketals of 4-bromobutanal and of 5-bromopentanal of the formula ##STR1## which comprises reacting 2,3-dihydroguran and 3,4-dihydro-2H-pyran respectively in a solvent in the presence of a catalyst with neopentylglycol and then brominating the resulting product. The invention also relates to the said ketal of 5-bromobutanal as such.

Abstract: A method of conducting a Diels-Alder reaction is provided comprising reacting a Diels-Alder diene comprising a 1,3-conjugated diene with a dienophile comprising an alpha,beta-unsaturated acetal or ketal in the presence of a protonating acid to yield a [4+2] cycloadduct.

Abstract: Cyclohexane derivatives of the formula IR.sup.1 --A.sup.1 --Z.sup.1 --A.sup.2 --R.sup.2 Iin whichR.sup.1 and R.sup.2 are each an alkyl group having 1-10 C atoms, in which one or two non-adjacent CH.sub.2 groups can also be replaced by O atoms and/or --CO-- groups and/or --CO--O-- groups and/or --CH.dbd.CH-- groups, one of the radicals R.sup.1 and R.sup.2 also being H, F, Cl, Br, CN or R.sup.3 --A.sup.3 --Z.sup.2 --,A.sup.1 is --A--, A.sup.4 --A-- or --A--A.sup.4 --,A is a trans-1,4-cyclohexylene group which can be substituted in the 2-, 3-, 5- and/or 6-position one or more times by F and/or Cl and/or Br and/or CN and/or an alkyl group or a fluorinated alkyl group which each have 1-10 C atoms and in which one or two non-adjacent CH.sub.2 groups can also be replaced by 0 atoms and/or --CO-- groups and/or --CO--O-- groups, and which may also be substituted in the 1- and/or 4-position,A.sup.2, A.sup.3 and A.sup.

Abstract: The new compound ##STR1## is prepared and converted to the new acetal ##STR2## which is reacted with an alkali phenolate or alkaline earth metal phenolate in the presence of copper or a copper compound as a catalyst and in the presence of a diluent at a temperature between about 100.degree. and 200.degree. C. to produce the new acetal ##STR3## which can be hydrolyzed to the corresponding aldehyde which is a known intermediate for pyrethroid-like insecticides.

Abstract: A compound of the formula ##STR1## wherein X has the formula --CR.sup.5 .dbd.CR.sup.6 --, --C.tbd.C-- or ##STR2## wherein ring A is phenyl, naphthyl or heterocyclic; wherein R.sup.1 is hydrogen, alkyl, alkanoyl or aroyl;wherein R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, each is an electron withdrawing substituent of each is hydrogen or alkyl, alkoxy or dialkylamino, provided that when ring A is phenyl or naphthyl at least one of R.sup.2, R.sup.3 and R.sup.4 is an electron-withdrawing substitutent;wherein R.sup.5 and R.sup.6, each is hydrogen, halogeno or alkyl;wherein R.sup.7 is alkyl or halogenoalkyl; and wherein R.sup.8 has the formula --Y--Q--R.sup.9 wherein Y is straight- or branched-chain alkylene or alkenylene; wherein Q is --O--, --S--, --SO-- or --SO.sub.2 --; andwherein R.sup.9 is alkyl or up to 6 carbon atoms which contains one or more defined substituents, processes for their manufacture and pharmaceutical compositions containing them.

Abstract: N-Aryl benzamides wherein the aryl group is a nitrogen containing heterocycle are useful as selective herbicidal agents. Compositions containing the novel benzamides and a herbicidal method of selective weed control are disclosed.

Abstract: An alkylene or dialkyl ketal of the formula ##STR1## wherein R.sup.3 is halo, carboxy or (C.sub.1 -C.sub.12)alkyl, alkoxy, acyl, acyloxy, carbalkoxy or alkylthio.R.sup.1 is (C.sub.1 -C.sub.12)alkyl, (C.sub.6 -C.sub.20)aryl or (C.sub.7 -C.sub.21)alkylaryl or aralkyl; andR.sup.2 is (C.sub.1 -C.sub.12)alkyl or the two R.sup.2 taken together are (C.sub.2 -C.sub.12)alkylene.An alpha-enol ether of the formula ##STR2## wherein R.sup.1 and R.sup.3 are as defined above and R.sup.2 is (C.sub.1 -C.sub.12)alkyl.

Abstract: Certain tellurium compounds have been found to have the ability to stimulate the in vivo and in vitro production of cytokines and their receptors. These compounds may be utilized in the treatment of certain tumors, autoimmune diseases, immune diseases and infectious diseases.

Abstract: The invention concerns novel 4-phenyl-1,3-dioxan-5-ylalkenoic acid derivatives of the formula I having cis relative stereochemistry at positions 4 and 5 of the dioxane ring and wherein Ra and Rb are variously hydrogen, alkyl, halogenoalkyl, alkenyl, and optionally substituted aryl or arylalkyl, Rc is hydroxy, alkoxy or alkanesulphonamido, n is 1 or 2, A is ethylene or vinylene, Y is (2-5C)polymethylene optionally substituted by alkyl, and benzene ring B is optionally substituted phenyl, or, when Rc is hydroxy, a salt thereof. The acid derivatives antagonize one or more of the actions of thromboxane A.sub.2 (TXA.sub.2) and are expected to be of value in those disease conditions in which TXA.sub.2 is involved. The invention also provides pharmaceutical compositions containing an acid derivative of formula I, and processes for their chemical production.

Abstract: Compounds of the formula IR.sup.1 --A.sup.1 --Z.sup.1 --A.sup.2 --R.sup.2 IwhereinR.sup.1 and R.sup.2 are each an alkyl group having 1-10 C atoms, in which one or two non-adjacent CH.sub.2 groups can also be replaced by O atoms and/or CO groups and/or --OCO-- groups and/or --COO-- groups and/or --CH.dbd.CH-- groups, or are F, Cl, Br, CN or R.sup.3 --A.sup.3 --Z.sup.2 --,A.sup.1 is --A--, --A.sup.4 --A-- or --A--A.sup.4 --,A is a 1,3-dioxane-2,5-diyl or 1,3-dithiane-2,5-diyl group which is monosubstituted or polysubstituted in the 2-position and/or 4-position by alkyl each having 1-10 C atoms and/or in the 5-position by alkyl, alkoxy, fluorinated alkyl or fluorinated alkoxy each having 1-5 C atoms, or by F, Cl, Br or CN,A.sup.2, A.sup.3 and A.sup.4 each are 1,3-dithiane-2,5-diyl, piperidine-1,4-diyl, 1,4-bicyclo[2,2,2]octylene, decahydronaphthalene-2,6-diyl, 1,2,3,4-tetrahydronaphthalene-2,6-diyl, 1,4-phenylene, 1,4-phenylene which is substituted by one or two F and/or Cl atoms and/or CH.sub.

Abstract: Liquid crystalline mixtures containing compounds of the formula ##STR1## wherein n stands for the number 0 or 1; X.sup.1 and X.sup.2 denote single covalent bonds or one of the symbols X.sup.1 and X.sup.2 also denotes --COO--, --OOC-- or --CH.sub.2 CH.sub.2 --; the rings A.sup.1, A.sup.2 and A.sup.3 represent 1,4-phenylene, 2-fluoro-1,4-phenylene or trans-1,4-cyclohexylene or one of these rings also represents a 2,5-disubstituted pyrimidine ring or a trans-2,5-disubstituted m-dioxane ring; R.sup.1 signifies 4-alkenyl or on a cyclohexyl ring also 2Z-alkenyl; and R.sup.2 denotes alkyl, alkoxy, --CN or --NCS,as well as the manufacture of these compounds and the use for electro-optical purposes are described.